CNS efficacy of ceritinib
N/A, Not applicable
I-ORR, intracranialobjective response rate
I-DCR, intracranialdisease control rate
a
best overall response in all sites of disease
b
patients with target lesions at baseline
Kim, et al. Lancet Oncol 2016 17(4): 452–63
Crino, et al. J Clin Oncol 2016 34(24): 2866–73; Felip, et al. ESMO 2016 (Abs. 1208O)
ALK inhibited pre-treated
ALK inhibitor
naïve
Patients with baseline
brain metastases
ASCEND-1
(n=75)
ASCEND-2
(n=100)
ASCEND-3
(n=49)
Systemic efficacy
a
ORR, %
56
33
57
DCR, %
N/A
74
88
Intracranial efficacy
b
n=28
n=20
n=13
I-ORR, %
36
45
61
I-DCR,%
61
80
77
INDICACIÓN PENDIENTE DE APROBACIÓN,
